...respectively. Ongoing work by GlaxoSmithKline plc includes testing GSK3494245 in preclinical models of visceral leishmaniasis. Knight Therapeutics Inc....

...business unit at the Fresenius Kabi subsidiary of Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY). Knight Therapeutics Inc....

...and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506); and Impavido miltefosine, a cholinephosphate cytidyltransferase inhibitor, from Knight Therapeutics Inc....

...a Priority Review voucher to speed approval of HIV drug Odefsey rilpivirine/emtricitabine/tenofovir alafenamide. It paid Knight Therapeutics Inc....

...Next steps could including testing the flotillin inhibitors in additional models of S. aureus infections. Knight Therapeutics Inc....
...Profounda Inc. , Roche , and Zydus Cadila Group market Impavido to treat leishmaniasis. Knight Therapeutics...

...evaluated flotillin small molecule inhibitors including Impavido miltefosine , zaragozic acid and 5-doxyl-stearic acid (5-DSA). Knight Therapeutics Inc....
...Impavido to treat leishmaniasis. The drug is an alkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase . Chris Lieu Impavido Miltefosine Knight Therapeutics Inc. Profounda...

...Gilead used a voucher to speed approval of HIV drug Odefsey rilpivirine/emtricitabine/tenofovir alafenamide. It paid Knight Therapeutics Inc....

...hours. Next steps could include optimizing and testing the compound in additional models of leishmaniasis. Knight Therapeutics Inc....
...Profunda Inc. , Roche , and Zydus Cadila Group market Impavido miltefosine to treat leishmaniasis. Knight Therapeutics...

...12/30 Mcap % chg Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) (A) 12/28/16 $28.7 NA $108.3 NA Knight Therapeutics Inc....

...and TD Securities. The figures include a 1.3 million share overallotment. Knight Therapeutics Inc. (TSX:GUD), Westmount, Quebec Alex Himes Knight Therapeutics Inc....